1. Home
  2. MESO vs CASH Comparison

MESO vs CASH Comparison

Compare MESO & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MESO
  • CASH
  • Stock Information
  • Founded
  • MESO 2004
  • CASH 1954
  • Country
  • MESO Australia
  • CASH United States
  • Employees
  • MESO N/A
  • CASH N/A
  • Industry
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • CASH Major Banks
  • Sector
  • MESO Health Care
  • CASH Finance
  • Exchange
  • MESO Nasdaq
  • CASH Nasdaq
  • Market Cap
  • MESO 1.7B
  • CASH 1.7B
  • IPO Year
  • MESO N/A
  • CASH N/A
  • Fundamental
  • Price
  • MESO $12.48
  • CASH $72.91
  • Analyst Decision
  • MESO Buy
  • CASH Hold
  • Analyst Count
  • MESO 4
  • CASH 3
  • Target Price
  • MESO $18.00
  • CASH $79.67
  • AVG Volume (30 Days)
  • MESO 305.9K
  • CASH 208.6K
  • Earning Date
  • MESO 02-26-2025
  • CASH 04-23-2025
  • Dividend Yield
  • MESO N/A
  • CASH 0.28%
  • EPS Growth
  • MESO N/A
  • CASH 12.57
  • EPS
  • MESO N/A
  • CASH 6.88
  • Revenue
  • MESO $5,670,000.00
  • CASH $719,617,000.00
  • Revenue This Year
  • MESO $228.57
  • CASH $12.98
  • Revenue Next Year
  • MESO $356.77
  • CASH $5.72
  • P/E Ratio
  • MESO N/A
  • CASH $10.57
  • Revenue Growth
  • MESO N/A
  • CASH 9.58
  • 52 Week Low
  • MESO $4.60
  • CASH $48.15
  • 52 Week High
  • MESO $22.00
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • MESO 34.58
  • CASH 43.77
  • Support Level
  • MESO $13.60
  • CASH $72.11
  • Resistance Level
  • MESO $14.45
  • CASH $76.80
  • Average True Range (ATR)
  • MESO 0.49
  • CASH 2.00
  • MACD
  • MESO 0.02
  • CASH 0.29
  • Stochastic Oscillator
  • MESO 23.50
  • CASH 44.28

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: